Anatara Lifesciences Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANR.AX research report →
Price Chart
About the company
Anatara Lifesciences Ltd is an Australian enterprise focused on researching, developing, and commercializing scientifically-validated therapies for digestive system ailments affecting both humans and animals. Its product portfolio includes Gastrointestinal ReProgramming (GRP), a proprietary blend combining bromelain with other evidence-based ingredients, specifically formulated to target the underlying issues of human gastrointestinal conditions such as irritable bowel syndrome and inflammatory bowel disease. The firm also offers 3FDC, designed to address anxiety, stress, or depression.
- CEO
- David Lionel Brookes
- IPO
- 2014
- Employees
- 7
- HQ
- Adelaide, SA, AU
Get TickerSpark's AI analysis on ANR.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.87M
- P/E
- -2.65
- PEG
- -0.04
- P/S
- 0.00
- P/B
- 4.00
- EV/EBITDA
- -1.12
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -101.34%
- ROIC
- -131.24%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-84+100.0%
- Op Income
- $-1,253,507
- Net Income
- $-933,230+52.3%
- EPS
- $-0.00+64.2%
- OCF Growth
- +85.1%
- FCF Growth
- +85.1%
- 52W High
- $0.02
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 0.69
- RSI (14)
- 26
- Avg Volume
- 239.06K
No earnings-call transcripts are available for ANR.AX yet.
- Free Float
- 73.4%
- Shares Outstanding
- 207.92M
- Float Shares
- 152.60M
Our ANR.AX coverage
Recent articles, reports, and earnings notes.
No research on ANR.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANR.AX report →